As of Feb 12
| +0.15 / +0.45%|
The 7 analysts offering 12-month price forecasts for Acorda Therapeutics Inc have a median target of 45.00, with a high estimate of 65.00 and a low estimate of 34.10. The median estimate represents a +33.81% increase from the last price of 33.63.
The current consensus among 8 polled investment analysts is to Buy stock in Acorda Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.